These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3146506)

  • 1. The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.
    Dominiak P; Grevel J; Abisch E; Grobecker H; Dennler HJ; Welzel D
    Eur J Clin Pharmacol; 1988; 35(1):53-7. PubMed ID: 3146506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bioavailability of alpha-acetyldigoxin from Card-Hydergin--a fixed combination of Hydergine and acetyldigoxin.
    Klotz U
    Int J Clin Pharmacol Biopharm; 1978 Mar; 16(3):116-8. PubMed ID: 649228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients.
    Sörgel F; Abisch E; Dennler HJ; Lang E
    Eur J Clin Pharmacol; 1984; 26(1):133-5. PubMed ID: 6714287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction.
    Althaus M; de Mey C; Ezan E; Ciecko-Michalska ; Kostka-Trabka E; Goszcz A; Retzow A
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):67-74. PubMed ID: 11270804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
    Clark BJ; Bucher T; Waite R
    J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].
    Mies R; Lang R; Weidinger G; Welzel D
    Arzneimittelforschung; 1983; 33(5):771-3. PubMed ID: 6683557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
    Woodcock BG; Herrmann W; Habedank WD
    Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
    Köberle S; Spiegel R
    Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
    Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
    Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of cotinine after oral and intravenous administration to man.
    De Schepper PJ; Van Hecken A; Daenens P; Van Rossum JM
    Eur J Clin Pharmacol; 1987; 31(5):583-8. PubMed ID: 3830243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers.
    Bohner H; Janiak PS; Nitsche V; Eichinger A; Schütz H
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):117-22. PubMed ID: 9089001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.